Pharmacy & Therapeutics - February 2009 - (Page 76)

DRUG FORECAST NEW DRUGS dose chemotherapy. Haematologica 2005; 90(9):1287–1288. Pönisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: Results of a phase I clinical trial. Br J Haematol 2008;143(2): 191–200. von Minckwitz G, Chernozemsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): A phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate, and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005; 16(8):871–877. Koster W, Stamatis G, Heider A, et al. Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Clin Drug Invest 2004; 24(10):611–618. Schmittel A, Knodler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007;55(1): 109–113. Hartmann JT, Mayer F, Schleicher J, et al. Bendamustine hydrochloride in patients with refractor y soft tissue sarcoma: A noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007;110(4):861–866. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 2007;18(5): 587–595. National Comprehensive Cancer Network. NCCN updates non-Hodgkin’s lymphoma guidelines, April 22, 2008. Available at: www.nccn.org/about/news/ newsinfo.asp?NewsID=136. Accessed October 2008. Cephalon receives FDA approval for Treanda, a novel chemotherapy for chronic lymphocytic leukemia, March 20, 2008. Available at: www.cephalon.com. Accessed October 2008. Cephalon receives FDA approval for Treanda to treat patients with relapsed, indolent non-Hodgkin’s lymphoma, October 31, 2008. Available at: www.cephalon.com. Accessed December 3, 2008. Center for Dr ug Evaluation and Research. Application No. NDA 22-249. Medical review(s), part 1. Available at: www.fda.gov/cder/foi/nda/2008/22249s 000_ SumR.pdf. Accessed September 2008. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14(1): 309–317. 17. Treanda (bendamustine hydrochloride) for injection, for intravenous infusion, prescribing information. Celphalon, revised March 2008. Available at: www. cephalon.com/fileadmin/newsroom/ assets/Treanda_pi.pdf. Accessed September 2008. 18. Balfour JA, Goa KL. Bendamustine. Drugs 2001;61(5):631–638; discussion, 639–640. 19. Knauf WU, Lissichkov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocyctic leukemia (B-CLL): Results of an international phase III study (Abstract 2043). Blood 2007;110:609a. 20. Koppler H, Heymanns J, Pandorf A, et al. Bendamustine plus mitoxantrone: A new effective treatment for advanced chronic lymphocytic leukaemia. Results of a phase I/II study. Leuk Lymphoma 2004; 45(5):911–913. 21. Lissitchkov T, Arnaudov G, Peytchev D, et al. Phase I/II study to evaluate doselimiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006;132(2):99–104. 22. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine, and prednisone (BOP) versus cyclophosphamide, vincristine, and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: Results of a randomised phase III trial (OSHO No. 19). J Cancer Res Clin Oncol 2006;132(2):105–112. 23. Weide R, Heymanns J, Gores A, et al. Bendamustine mitoxantrone and rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma 2002;43(2): 327–331. 24. Weide R, Pandorf A, Heymanns J, et al. Bendamustine/mitoxantrone/rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004;45(12): 2445–2449. 25. Koenigsmann M, Knauf W, Herold M, et al. Fludarabine and bendamustine in refractor y and relapsed indolent lymphoma: A multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004;45(9):1821–1827. 26. Center for Dr ug Evaluation and Research. Application No. NDA 22-249. Medical review(s), part 2. Available at: www.fda.gov/cder/foi/nda/2008/22249s 000_SumR.pdf. Accessed September 2008. 27. Murray L. Red Book: Pharmacy’s Fundamental Reference. Montvale, NJ: Thomson PDR; 2008. I continued from page 70 DRUG NEWS 6. 7. 8. 9. 10. the mother’s own metabolism is critical. In this study, mean caffeine intake was 159 mg/day, dropping from 238 mg/day before pregnancy to 139 mg/day between weeks 5 and 12 of gestation. Most of the caffeine came from tea, followed by coffee, cola drinks, and chocolate. Soft drinks, hot chocolate, energy drinks, alcoholic drinks, and over-the-counter medications each contributed 2% or less. Of 2,635 women in the study, 343 experienced restricted fetal growth. More than 200 mg/day of caffeine during pregnancy was associated with a reduction in birth weight of 60 to 70 g. The higher the caffeine intake, the greater the reduction in birth weight in all trimesters. Women contemplating pregnancy should try to reduce their caffeine intake before conception. Source: BMJ, November 3, 2008, 337: a2332 Hormone Therapy And Incontinence Postmenopausal women who take hormone therapy have a moderately higher risk of urinary incontinence, compared with women who have never used hormone therapy, say researchers from Brigham and Women’s Hospital and Harvard Medical School and University of Pittsburgh. Their analysis of data from the Nurses’ Health Study showed that 14% of 7,341 postmenopausal women who had reported no urinary incontinence in 2001 were having at least monthly episodes within two years; 4% began having incontinent episodes at least weekly. Among the women with at least one episode per week, more than half of the episodes were classified as stress incontinence and 18% were classified as urge incontinence. The similarities in the relationship of urinary incontinence with hormone therapy in the age groups suggest that mulcontinued on page 105 11. 12. 13. 14. 15. 16. 76 P&T® • February 2009 • Vol. 34 No. 2 http://www.cephalon.com/fileadmin/newsroom/assets/Treanda_pi.pdf http://www.cephalon.com/fileadmin/newsroom/assets/Treanda_pi.pdf http://www.cephalon.com/fileadmin/newsroom/assets/Treanda_pi.pdf http://www.nccn.org/about/news/newsinfo.asp?NewsID=136 http://www.nccn.org/about/news/newsinfo.asp?NewsID=136 http://www.cephalon.com http://www.cephalon.com http://www.fda.gov/cder/foi/nda/2008/22249s000_SumR.pdf http://www.fda.gov/cder/foi/nda/2008/22249s000_SumR.pdf http://www.fda.gov/cder/foi/nda/2008/22249s000_SumR.pdf http://www.fda.gov/cder/foi/nda/2008/22249s000_SumR.pdf

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - February 2009

Pharmacy & Therapeutics - February 2009 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/New Medical Devices Drug Forecast Pushing an Expanded Role for Pharmacists Better Asthma Management with Advanced Technology Pharmaceutical Approval Update 58th Annual Meeting, American Society of Human Genetics, 2008 American Society of Hematology, 50th Annual Meeting and Exposition 2008 San Antonio Breast Cancer Symposium Stahl’s Essential Psychopharmacology, 3rd Edition Author Guidelines

Pharmacy & Therapeutics - February 2009

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.